Solid Biosciences (SLDB) Enterprise Value (2018 - 2026)

Solid Biosciences has reported Enterprise Value for 10 years, with the latest figure at -$297.7 million in Q1 2026.

• Quarterly Enterprise Value fell 41.36% year-over-year to -$297.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$297.7 million (down 41.36% YoY) and the FY2025 annual result came in at -$187.8 million, down 134.12% from the prior year.
• Enterprise Value eased to -$297.7 million in Q1 2026 per SLDB's latest filing, from -$187.8 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$49.0 million in Q3 2022 and troughed at -$297.7 million in Q1 2026.
• A 5-year average of -$174.0 million and a median of -$185.5 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value soared 72.82% in 2022, then tumbled 193.67% in 2023.
• Over 5 years, Enterprise Value stood at -$213.7 million in 2022, then surged by 42.15% to -$123.6 million in 2023, then surged by 35.11% to -$80.2 million in 2024, then sank by 134.12% to -$187.8 million in 2025, then slumped by 58.5% to -$297.7 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$297.7 million, -$187.8 million, and -$236.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.